# EDGAR Filing Document

**Accession Number:** 0001377121
**File Stem:** 0001104659-25-063038
**Filing Date:** 2025-6
**Character Count:** 6512
**Document Hash:** 8025b77f3cfb046f5a521881b3f8fa7e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-063038.hdr.sgml**: 20250626

**ACCESSION NUMBER**: 0001104659-25-063038

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250620

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250626

**DATE AS OF CHANGE**: 20250626

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Protagonist Therapeutics, Inc
- **CENTRAL INDEX KEY:** 0001377121
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 980505495
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37852
- **FILM NUMBER:** 251080433

**BUSINESS ADDRESS:**
- **STREET 1:** 7707 GATEWAY BLVD., SUITE 140
- **CITY:** NEWARK
- **STATE:** CA
- **ZIP:** 94560-1160
- **BUSINESS PHONE:** (510) 474-0170

**MAIL ADDRESS:**
- **STREET 1:** 7707 GATEWAY BLVD., SUITE 140
- **CITY:** NEWARK
- **STATE:** CA
- **ZIP:** 94560-1160

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Protagonist Therapeutics Inc
- **DATE OF NAME CHANGE:** 20130605

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Protagonist Inc
- **DATE OF NAME CHANGE:** 20061002

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 20, 2025**

**PROTAGONIST THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37852** | **98-0505495** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

**Protagonist Therapeutics, Inc.** 

**7707 Gateway Blvd., Suite 140**

**Newark, California 94560-1160**

(Address of principal executive offices, including zip code)

**(510) 474-0170**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which<br> registered** |
| Common Stock, par value $0.00001 | PTGX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

On June 20, 2025, Protagonist Therapeutics, Inc., a Delaware corporation (the "Company"), held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on April 23, 2025, the record date for the Annual Meeting, there were 61,957,230 shares of common stock, par value $0.00001 per share (the "Common Stock"), entitled to vote at the meeting.

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

At the Annual Meeting, the stockholders voted on the three proposals listed below. The proposals are described in detail in the Company's definitive proxy statement for the Annual Meeting, which was filed with the Securities and Exchange Commission on April 29, 2025. The results of the proposals voted upon at the Annual Meeting were:

**Proposal 1 —** To elect the two Class III director nominees to hold office until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified. Each of the two nominees was so elected, with the votes thereon as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Final Voting Results** | **Final Voting Results** | **Final Voting Results** |
| **Nominee** | **For** | **Withheld** | **Broker Non-Votes** |
| Harold E. Selick, Ph.D. | 44822907 | 9210036 | 1918517 |
| Bryan Giraudo | 42499790 | 11533153 | 1918517 |

---

**Proposal 2 —** To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. This proposal was approved by the requisite vote, with the votes thereon as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Final Voting Results** | **Final Voting Results** | **Final Voting Results** | **Final Voting Results** |
| **For** | **Against** | **Abstentions** | **Broker Non-Votes** |
| 50844517 | 2850473 | 337953 | 1918517 |

---

**Proposal 3 —** To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025. This proposal was approved by the requisite vote, with the votes thereon as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Final Voting Results** | **Final Voting Results** | **Final Voting Results** | **Final Voting Results** |
| **For** | **Against** | **Abstentions** | **Broker Non-Votes** |
| 55480739 | 74233 | 396488 | -- |

---

No other matters were submitted for stockholder action.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Protagonist Therapeutics, Inc.** | **Protagonist Therapeutics, Inc.** |
| Dated: June 26, 2025 |  |  |
|  | By: | /s/ Asif Ali |
|  |  | Asif Ali |
|  |  | Executive Vice President, Chief Financial Officer |

---